Functional neuroprotection and efficient regulation of GDNF using destabilizing domains in a rodent model of Parkinson's disease

Molecular Therapy

Volumn 21, Issue 12, 2013, Pages 2169-2180

  Quintino, Luis ^a   Manfré, Giuseppe ^a   Wettergren, Erika Elgstrand ^a   Namislo, Angrit ^a   Isaksson, Christina ^a   Lundberg, Cecilia ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR RECEPTOR; HYBRID PROTEIN; TRIMETHOPRIM;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DESTABILIZING DOMAIN; DRUG MECHANISM; GENE EXPRESSION REGULATION; IN VITRO STUDY; IN VIVO STUDY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PROTEIN CLEAVAGE; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA PARS COMPACTA; VALIDATION PROCESS;

ANIMALIA; RODENTIA;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; FEMALE; GENE EXPRESSION REGULATION; GENETIC THERAPY; GENETIC VECTORS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HEK293 CELLS; HUMANS; LENTIVIRUS; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT FUSION PROTEINS; REPRODUCIBILITY OF RESULTS; TETRAHYDROFOLATE DEHYDROGENASE; TRIMETHOPRIM;

EID: 84890118525     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.169     Document Type: Article

References (40)

1. Meissner, WG, Frasier, M, Gasser, T, Goetz, CG, Lozano, A, Piccini, P et al. (2011). Priorities in Parkinson's disease research. Nat Rev Drug Discov 10: 377-393
2. Bjorklund, T and Kordower, JH (2010). Gene therapy for parkinson's disease. Mov Disord 25 Suppl 1: S161-S173
3. Even Ram, S and Galun, E (2009). AAV2-GDNF gene therapy for parkinson's disease. Hum Gene Ther 20: 430-431
4. Hoffer, BJ and Harvey, BK (2011). Is GDNF beneficial in Parkinson disease? Nat Rev Neurol 7: 600-602
5. Dowd, E, Monville, C, Torres, EM, Wong, LF, Azzouz, M, Mazarakis, ND et al. (2005). Lentivector-mediated delivery of GDNF protects complex motor functions relevant to human Parkinsonism in a rat lesion model. Eur J Neurosci 22: 2587-2595
6. Eslamboli, A, Georgievska, B, Ridley, RM, Baker, HF, Muzyczka, N, Burger, C et al. (2005). Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of parkinson's disease. J Neurosci 25: 769-777
7. Georgievska, B, Kirik, D and Björklund, A (2002). Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer. Exp Neurol 177: 461-474
8. Ciesielska, A, Mittermeyer, G, Hadaczek, P, Kells, AP, Forsayeth, J and Bankiewicz, KS (2011). Anterograde axonal transport of AAV2-GDNF in rat basal ganglia. Mol Ther 19: 922-927
9. Kirik, D, Rosenblad, C, Bjorklund, A and Mandel, RJ (2000). Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: Intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci 20: 4686-4700
10. Rosenblad, C, Georgievska, B and Kirik, D (2003). Long-term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system. Eur J Neurosci 17: 260-270
11. Hovland, DN Jr, Boyd, RB, Butt, MT, Engelhardt, JA, Moxness, MS, Ma, MH et al. (2007). Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF in rhesus monkeys. Toxicol Pathol 35: 1013-1029
12. Manfredsson, FP, Tumer, N, Erdos, B, Landa, T, Broxson, CS, Sullivan, LF et al. (2009). Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity. Mol Ther 17: 980-991
13. Manfredsson, FP, Burger, C, Rising, AC, Zuobi-Hasona, K, Sullivan, LF, Lewin, AS et al. (2009). Tight Long-term dynamic doxycycline responsive nigrostriatal GDNF using a single rAAV vector. Mol Ther 17: 1857-1867
14. Manfredsson, FP, Bloom, DC and Mandel, RJ (2012). Regulated protein expression for in vivo gene therapy for neurological disorders: Progress, strategies, and issues. Neurobiol Dis 48: 212-221
15. Banaszynski, LA, Chen, LC, Maynard-Smith, LA, Ooi, AG and Wandless, TJ (2006). A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules. Cell 126: 995-1004
16. Banaszynski, LA, Sellmyer, MA, Contag, CH, Wandless, TJ and Thorne, SH (2008). Chemical control of protein stability and function in living mice. Nat Med 14: 1123-1127
17. Iwamoto, M, Björklund, T, Lundberg, C, Kirik, D and Wandless, TJ (2010). A general chemical method to regulate protein stability in the mammalian central nervous system. Chem Biol 17: 981-988
18. Tai, K, Quintino, L, Isaksson, C, Gussing, F and Lundberg, C (2012). Destabilizing domains mediate reversible transgene expression in the brain. PLoS ONE 7: E46269
19. Petersen, TN, Brunak, S, von Heijne, G and Nielsen, H (2011). SignalP 4.0: Discriminating signal peptides from transmembrane regions. Nat Methods 8: 785-786
20. Vembar, SS and Brodsky, JL (2008). One step at a time: Endoplasmic reticulumassociated degradation. Nat Rev Mol Cell Biol 9: 944-957
21. Thomas, G (2002). Furin at the cutting edge: From protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol 3: 753-766
22. Duckert, P, Brunak, S and Blom, N (2004). Prediction of proprotein convertase cleavage sites. Protein Eng Des Sel 17: 107-112
23. Xiao, H, Hirata, Y, Isobe, K and Kiuchi, K (2002). Glial cell line-derived neurotrophic factor up-regulates the expression of tyrosine hydroxylase gene in human neuroblastoma cell lines. J Neurochem 82: 801-808
24. Quintino, L, Baudet, A, Larsson, J and Lundberg, C (2013). FACS binding assay for analysing GDNF interactions. J Neurosci Methods 218: 25-28
25. Sellmyer, MA, Chen, LC, Egeler, EL, Rakhit, R and Wandless, TJ (2012). Intracellular context affects levels of a chemically dependent destabilizing domain. PLoS ONE 7: E43297
26. Decressac, M, Kadkhodaei, B, Mattsson, B, Laguna, A, Perlmann, T and Björklund, A (2012). a-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Sci Transl Med 4: 163ra156
27. Kirik, D, Rosenblad, C and Björklund, A (1998). Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol 152: 259-277
28. Georgievska, B, Kirik, D, Rosenblad, C, Lundberg, C and Björklund, A (2002). Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. Neuroreport 13: 75-82
29. Chtarto, A, Yang, X, Bockstael, O, Melas, C, Blum, D, Lehtonen, E et al. (2007). Controlled delivery of glial cell line-derived neurotrophic factor by a single tetracycline-inducible AAV vector. Exp Neurol 204: 387-399
30. Hadaczek, P, Beyer, J, Kells, A, Narrow, W, Bowers, W, Federoff, HJ et al. (2011). Evaluation of an AAV2-based rapamycin-regulated glial cell line-derived neurotrophic factor (GDNF) expression vector system. PLoS ONE 6: E27728
31. Yang, X, Mertens, B, Lehtonen, E, Vercammen, L, Bockstael, O, Chtarto, A et al. (2009). Reversible neurochemical changes mediated by delayed intrastriatal glial cell line-derived neurotrophic factor gene delivery in a partial Parkinson's disease rat model. J Gene Med 11: 899-912
32. Szulc, J, Wiznerowicz, M, Sauvain, MO, Trono, D and Aebischer, P (2006). A versatile tool for conditional gene expression and knockdown. Nat Methods 3: 109-116
33. Chtarto, A, Tenenbaum, L, Velu, T, Brotchi, J, Levivier, M and Blum, D (2003). Minocycline-induced activation of tetracycline-responsive promoter. Neurosci Lett 352: 155-158
34. Georgievska, B, Jakobsson, J, Persson, E, Ericson, C, Kirik, D and Lundberg, C (2004). Regulated delivery of glial cell line-derived neurotrophic factor into rat striatum, using a tetracycline-dependent lentiviral vector. Hum Gene Ther 15: 934-944
35. Latta-Mahieu, M, Rolland, M, Caillet, C, Wang, M, Kennel, P, Mahfouz, I et al. (2002). Gene transfer of a chimeric trans-activator is immunogenic and results in short-lived transgene expression. Hum Gene Ther 13: 1611-1620
36. Gleckman, R, Blagg, N and Joubert, DW (1981). Trimethoprim: Mechanisms of action, antimicrobial activity, bacterial resistance, pharmacokinetics, adverse reactions, and therapeutic indications. Pharmacotherapy 1: 14-20
37. Tu, YH, Allen, LV Jr, Fiorica, VM and Albers, DD (1989). Pharmacokinetics of trimethoprim in the rat. J Pharm Sci 78: 556-560
38. Wettergren, EE, Gussing, F, Quintino, L and Lundberg, C (2012). Novel diseasespecific promoters for use in gene therapy for parkinson's disease. Neurosci Lett 530: 29-34
39. Zufferey, R, Nagy, D, Mandel, RJ, Naldini, L and Trono, D (1997). Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 15: 871-875
40. Cederfjäll, E, Sahin, G, Kirik, D and Björklund, T (2012). Design of a single AAV vector for coexpression of TH and GCH1 to establish continuous DOPA synthesis in a rat model of parkinson's disease. Mol Ther 20: 1315-1326